TY - JOUR T1 - Desogestrel POM to P: for the few not the many? JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull DO - 10.1136/dtb.2021.000049 SP - dtb-2021-000049 AU - David Phizackerley AU - Joanna Girling AU - James A Cave Y1 - 2021/08/22 UR - http://dtb.bmj.com/content/early/2021/08/22/dtb.2021.000049.abstract N2 - Until now, progestogen-only contraceptive pills (POPs) have been available as prescription-only medicines (POMs). Following a consultation process earlier in the year, the Medicines and Healthcare products Regulatory Agency (MHRA) announced that two products containing 75 mcg desogestrel will be available to purchase from community pharmacies ‘increasing choice for women in the ways in which they can access contraception’.1 Both products will be accompanied by training materials for pharmacy staff and a checklist for use during consultations. Desogestrel is regarded as safe for most women and few medical conditions restrict the use of POPs, although the summaries of product characteristics state that ‘safety and efficacy in adolescents below 18 years has not been established’.2–4The reclassification of progestogen-only contraceptives as pharmacy … ER -